close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Atea Pharmaceuticals, Inc. - common stock (NQ:AVIR)

4.155 +0.055 (+1.34%)
Delayed Quote Updated: 3:52 PM EST, Nov 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Atea Pharmaceuticals, Inc. - common stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic Partnerships
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
After Failed COVID-19 Drug Trial, Atea Pharmaceuticals Touts Encouraging Data From Mid-Stage Hepatitis C Study ↗
Atea Pharmaceuticals reports 98% SVR12 in a Phase 2 hepatitis C study, supporting an eight-week treatment plan with bemnifosbuvir and ruzasvir. 
Via Benzinga
News headline image
Atea Pharmaceuticals Announces Positive Results from Phase 2 Study of Bemnifosbuvir and Ruzasvir Regimen for Treatment of Hepatitis C Virus (HCV)
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals to Present and Provide a Business Update at the 7th Annual Evercore HealthCONx Conference
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Recap: Atea Pharmaceuticals Q4 Earnings ↗
 
Via Benzinga
News headline image
Atea Pharmaceuticals Earnings Preview ↗
 
Via Benzinga
News headline image
Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals to Present New Data Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals' COVID-19 Treatment Flunks In Late-Stage Study, Blames 'Constantly Evolving' Virus ↗
Atea Pharmaceuticals' Phase 3 SUNRISE-3 trial for bemnifosbuvir in COVID-19 patients did not meet the primary endpoint. The company remains focused on its hepatitis C combination therapy. 
Via Benzinga
News headline image
Adobe, SelectQuote, Similarweb And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Atea Pharmaceuticals Provides Update on Global Phase 3 SUNRISE-3 Trial Evaluating Bemnifosbuvir for Treatment of COVID-19
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals Announces Publication of Additional Data Further Highlighting Bemnifosbuvir’s Metabolic Activation Pathway
New Data Further Elucidates Bemnifosbuvir’s Metabolic Activation Pathway, Critical to its Mechanism of Action as an Antiviral Therapy for Treatment of COVID-19, HCV and Potentially a Broad Range of RNA... 
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call on August 7, 2024
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals Shares Promising Data From Therapy Study For Hepatitis C Virus ↗
Atea Pharmaceuticals announces 97% SVR12 in Phase 2 HCV study of bemnifosbuvir. Data shows high efficacy, safety, and low resistance risk. 
Via Benzinga
News headline image
Atea Pharmaceuticals Presents Positive Initial Phase 2 Data for Bemnifosbuvir and Ruzasvir Combination for Treatment of Hepatitis C Virus at EASL Congress 2024
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
AVIR Stock Earnings: Atea Pharmaceuticals Misses EPS for Q1 2024 ↗
AVIR stock results show that Atea Pharmaceuticals missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Atea Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
5 Under 10: Low Share Price, Debt Free, Lots Of Cash ↗
A look at five low-priced stocks with lots of cash per share, and no or very low debt. Most of them have very low-cap stocks and should be considered very speculative. 
Via Talk Markets
News headline image
Atea Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call on May 14, 2024
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals' Hepatitis C Virus Candidate Shows Efficacy ↗
Atea Pharmaceuticals Inc (NASDAQ: AVIR) reported initial data from the first 52 patients in the lead-in cohort of its Phase 2 combination eight-week study of bemnifosbuvir and ruzasvir (RZR) for 
Via Benzinga
News headline image
Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.